<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD07360000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P01308</UniProt_ID>
  <Seq_Length>110</Seq_Length>
  <Molecule_Weight>11981</Molecule_Weight>
  <KEGG_ID>hsa:3630</KEGG_ID>
  <Orthology_ID>K04526</Orthology_ID>
  <Function_Summary>Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.</Function_Summary>
  <Pfam_ID>PF00049:Insulin</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Insulin B chain</Alias>
      <Alias>Insulin A chain</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with the insulin-like growth factor receptor.</Detail>
      <Keyword>Insulin-like growth factor receptor binding</Keyword>
      <Ontology_ID>GO:0005159</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>The action characteristic of a hormone, any substance formed in very small amounts in one specialized organ or group of cells and carried (sometimes in the bloodstream) to another organ or group of cells in the same organism, upon which it has a specific regulatory action. The term was originally applied to agents with a stimulatory physiological action in vertebrate animals (as opposed to a chalone, which has a depressant action). Usage is now extended to regulatory compounds in lower animals and plants, and to synthetic substances having comparable effects; all bind receptors and trigger some biological process.</Detail>
      <Keyword>Hormone activity</Keyword>
      <Ontology_ID>GO:0005179</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with the insulin receptor.</Detail>
      <Keyword>Insulin receptor binding</Keyword>
      <Ontology_ID>GO:0005158</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>47</Position>
      <Original>Gly</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>29</Position>
      <Original>His</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>49</Position>
      <Original>Phe</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>46</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>89</Position>
      <Original>Arg</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>89</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>32</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>96</Position>
      <Original>Cys</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>101</Position>
      <Original>Ser</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>43</Position>
      <Original>Cys</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>55</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>108</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>35</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>84</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>90</Position>
      <Original>Gly</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>48</Position>
      <Original>Phe</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>24</Position>
      <Original>Ala</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>89</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>32</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>48</Position>
      <Original>Phe</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>6</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>34</Position>
      <Original>His</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>68</Position>
      <Original>Leu</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>92</Position>
      <Original>Val</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>103</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>96</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>6</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving fatty acids.</Detail>
      <Keyword>Negative regulation of fatty acid metabolic process</Keyword>
      <Ontology_ID>GO:0045922</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The change in morphology and behavior of an alpha-beta T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.</Detail>
      <Keyword>Alpha-beta T cell activation</Keyword>
      <Ontology_ID>GO:0046631</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of glycolysis.</Detail>
      <Keyword>Positive regulation of glycolysis</Keyword>
      <Ontology_ID>GO:0045821</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of the insulin receptor binding to insulin.</Detail>
      <Keyword>Insulin receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0008286</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y. Includes the formation of carbohydrate derivatives by the addition of a carbohydrate residue to another molecule.</Detail>
      <Keyword>Carbohydrate metabolic process</Keyword>
      <Ontology_ID>GO:0005975</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the protein kinase B signaling cascade, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B.</Detail>
      <Keyword>Positive regulation of protein kinase B signaling cascade</Keyword>
      <Ontology_ID>GO:0051897</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds.</Detail>
      <Keyword>Negative regulation of protein catabolic process</Keyword>
      <Ontology_ID>GO:0042177</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents or reduces the frequency, rate or extent of feeding behavior.</Detail>
      <Keyword>Negative regulation of feeding behavior</Keyword>
      <Ontology_ID>GO:2000252</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that mediates the transfer of information from one cell to another.</Detail>
      <Keyword>Cell-cell signaling</Keyword>
      <Ontology_ID>GO:0007267</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of mitosis.</Detail>
      <Keyword>Positive regulation of mitosis</Keyword>
      <Ontology_ID>GO:0045840</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of DNA replication.</Detail>
      <Keyword>Positive regulation of DNA replication</Keyword>
      <Ontology_ID>GO:0045740</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the regulated release of cytokines from a cell or group of cells.</Detail>
      <Keyword>Positive regulation of cytokine secretion</Keyword>
      <Ontology_ID>GO:0050715</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.</Detail>
      <Keyword>Positive regulation of lipid biosynthetic process</Keyword>
      <Ontology_ID>GO:0046889</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of events that restore integrity to a damaged tissue, following an injury.</Detail>
      <Keyword>Wound healing</Keyword>
      <Ontology_ID>GO:0042060</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving amino acids.</Detail>
      <Keyword>Regulation of cellular amino acid metabolic process</Keyword>
      <Ontology_ID>GO:0006521</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the phosphorylation of peptidyl-tyrosine.</Detail>
      <Keyword>Positive regulation of peptidyl-tyrosine phosphorylation</Keyword>
      <Ontology_ID>GO:0050731</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the maintenance of an internal steady state of glucose within an organism or cell.</Detail>
      <Keyword>Glucose homeostasis</Keyword>
      <Ontology_ID>GO:0042593</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the phosphatidylinositol 3-kinase cascade.</Detail>
      <Keyword>Positive regulation of phosphatidylinositol 3-kinase cascade</Keyword>
      <Ontology_ID>GO:0014068</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of a G-protein coupled receptor binding to its physiological ligand.</Detail>
      <Keyword>G-protein coupled receptor protein signaling pathway</Keyword>
      <Ontology_ID>GO:0007186</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the import of the hexose monosaccharide glucose into a cell or organelle.</Detail>
      <Keyword>Positive regulation of glucose import</Keyword>
      <Ontology_ID>GO:0046326</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of vasodilation.</Detail>
      <Keyword>Negative regulation of vasodilation</Keyword>
      <Ontology_ID>GO:0045908</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>An acute inflammatory response that involves non-antibody proteins whose concentrations in the plasma increase in response to infection or injury of homeothermic animals.</Detail>
      <Keyword>Acute-phase response</Keyword>
      <Ontology_ID>GO:0006953</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of activity of the transcription factor NF-kappaB.</Detail>
      <Keyword>Positive regulation of NF-kappaB transcription factor activity</Keyword>
      <Ontology_ID>GO:0051092</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of cell growth.</Detail>
      <Keyword>Positive regulation of cell growth</Keyword>
      <Ontology_ID>GO:0030307</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the activity of the enzyme nitric-oxide synthase.</Detail>
      <Keyword>Positive regulation of nitric-oxide synthase activity</Keyword>
      <Ontology_ID>GO:0051000</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate, or extent of an acute inflammatory response.</Detail>
      <Keyword>Negative regulation of acute inflammatory response</Keyword>
      <Ontology_ID>GO:0002674</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the maintenance of an internal steady state of fatty acid within an organism or cell.</Detail>
      <Keyword>Fatty acid homeostasis</Keyword>
      <Ontology_ID>GO:0055089</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of cell differentiation.</Detail>
      <Keyword>Positive regulation of cell differentiation</Keyword>
      <Ontology_ID>GO:0045597</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the frequency, rate or extent of insulin receptor signaling.</Detail>
      <Keyword>Positive regulation of insulin receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0046628</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops or reduces the activity of the enzyme NAD(P)H oxidase.</Detail>
      <Keyword>Negative regulation of NAD(P)H oxidase activity</Keyword>
      <Ontology_ID>GO:0033861</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways by which a cell derives energy from stored compounds such as fats or glycogen.</Detail>
      <Keyword>Energy reserve metabolic process</Keyword>
      <Ontology_ID>GO:0006112</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the MAPK cascade.</Detail>
      <Keyword>Positive regulation of MAPKKK cascade</Keyword>
      <Ontology_ID>GO:0043410</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving glucose, the aldohexose gluco-hexose. D-glucose is dextrorotatory and is sometimes known as dextrose; it is an important source of energy for living organisms and is found free as well as combined in homo- and hetero-oligosaccharides and polysaccharides.</Detail>
      <Keyword>Glucose metabolic process</Keyword>
      <Ontology_ID>GO:0006006</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of transmembrane transporter activity.</Detail>
      <Keyword>Regulation of transmembrane transporter activity</Keyword>
      <Ontology_ID>GO:0022898</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of nitric oxide.</Detail>
      <Keyword>Positive regulation of nitric oxide biosynthetic process</Keyword>
      <Ontology_ID>GO:0045429</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the phosphorylation by a protein of one or more of its own residues.</Detail>
      <Keyword>Positive regulation of protein autophosphorylation</Keyword>
      <Ontology_ID>GO:0031954</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed movement of the hexose monosaccharide glucose into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.</Detail>
      <Keyword>Glucose transport</Keyword>
      <Ontology_ID>GO:0015758</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of cell migration.</Detail>
      <Keyword>Positive regulation of cell migration</Keyword>
      <Ontology_ID>GO:0030335</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of the endocrine pancreas over time, from its formation to the mature structure. The endocrine pancreas is made up of islet cells that produce insulin, glucagon and somatostatin.</Detail>
      <Keyword>Endocrine pancreas development</Keyword>
      <Ontology_ID>GO:0031018</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency or extent of a phase of elevated metabolic activity, during which oxygen consumption increases made as a defense response ; this leads to the production, by an NADH dependent system, of hydrogen peroxide (H2O2), superoxide anions and hydroxyl radicals.</Detail>
      <Keyword>Negative regulation of respiratory burst involved in inflammatory response</Keyword>
      <Ontology_ID>GO:0060266</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the controlled release of a protein from a cell or group of cells.</Detail>
      <Keyword>Negative regulation of protein secretion</Keyword>
      <Ontology_ID>GO:0050709</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the rate or extent of cell proliferation.</Detail>
      <Keyword>Positive regulation of cell proliferation</Keyword>
      <Ontology_ID>GO:0008284</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the rate frequency or extent of a phase of elevated metabolic activity, during which oxygen consumption increases; this leads to the production, by an NADH dependent system, of hydrogen peroxide (H2O2), superoxide anions and hydroxyl radicals.</Detail>
      <Keyword>Positive regulation of respiratory burst</Keyword>
      <Ontology_ID>GO:0060267</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the regulated release of insulin.</Detail>
      <Keyword>Regulation of insulin secretion</Keyword>
      <Ontology_ID>GO:0050796</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of glycogen.</Detail>
      <Keyword>Negative regulation of glycogen catabolic process</Keyword>
      <Ontology_ID>GO:0045818</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis.</Detail>
      <Keyword>Negative regulation of gluconeogenesis</Keyword>
      <Ontology_ID>GO:0045721</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of vasodilation.</Detail>
      <Keyword>Positive regulation of vasodilation</Keyword>
      <Ontology_ID>GO:0045909</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A cascade of at least three protein kinase activities culminating in the phosphorylation and activation of a MAP kinase. MAPKKK cascades lie downstream of numerous signaling pathways.</Detail>
      <Keyword>MAPKKK cascade</Keyword>
      <Ontology_ID>GO:0000165</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that initiates the activity of the inactive enzyme protein kinase B.</Detail>
      <Keyword>Activation of protein kinase B activity</Keyword>
      <Ontology_ID>GO:0032148</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glycogen.</Detail>
      <Keyword>Positive regulation of glycogen biosynthetic process</Keyword>
      <Ontology_ID>GO:0045725</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptosis.</Detail>
      <Keyword>Negative regulation of apoptosis</Keyword>
      <Ontology_ID>GO:0043066</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of lipids.</Detail>
      <Keyword>Negative regulation of lipid catabolic process</Keyword>
      <Ontology_ID>GO:0050995</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the hydrolysis of a peptide bond or bonds within a protein.</Detail>
      <Keyword>Negative regulation of proteolysis</Keyword>
      <Ontology_ID>GO:0045861</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <Molecule_Seq>
    <Protein_Seq>MALWMRLLPLLALLALWGPDPAAAFVNQHLCGSHLVEALYLVCGERGFFYTPKTRREAEDLQVGQVELGGGPGAGSLQPLALEGSLQKRGIVEQCCTSICSLYQLENYCN</Protein_Seq>
    <DNA_Seq>AGCCCTCCAGGACAGGCTGCATCAGAAGAGGCCATCAAGCAGATCACTGTCCTTCTGCCATGGCCCTGTGGATGCGCCTCCTGCCCCTGCTGGCGCTGCTGGCCCTCTGGGGACCTGACCCAGCCGCAGCCTTTGTGAACCAACACCTGTGCGGCTCACACCTGGTGGAAGCTCTCTACCTAGTGTGCGGGGAACGAGGCTTCTTCTACACACCCAAGACCCGCCGGGAGGCAGAGGACCTGCAGGTGGGGCAGGTGGAGCTGGGCGGGGGCCCTGGTGCAGGCAGCCTGCAGCCCTTGGCCCTGGAGGGGTCCCTGCAGAAGCGTGGCATTGTGGAACAATGCTGTACCAGCATCTGCTCCCTCTACCAGCTGGAGAACTACTGCAACTAGACGCAGCCCGCAGGCAGCCCCACACCCGCCGCCTCCTGCACCGAGAGAGATGGAATAAAGCCCTTGAACCAGCAAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Pancreas</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Blood</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Endosome lumen</CellLocal>
      <Ontology_ID>GO:0031904</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Stored secretory granule</CellLocal>
      <Ontology_ID>GO:0030141</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Golgi lumen</CellLocal>
      <Ontology_ID>GO:0005796</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular region</CellLocal>
      <Ontology_ID>GO:0005576</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular space</CellLocal>
      <Ontology_ID>GO:0005615</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Endoplasmic reticulum lumen</CellLocal>
      <Ontology_ID>GO:0005788</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>INS</Gene_Name>
    <Gene_ID>3630</Gene_ID>
    <Genbank_ACCN>NM_000207</Genbank_ACCN>
    <Protein_ACCN>NP_000198</Protein_ACCN>
    <HGNC_ID>6081</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/3630</Gene_URL>
    <UCSC_ID>uc001lvn.2</UCSC_ID>
    <EMBL_ID>ENSG00000254647</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Fibrocalculous Pancreatopathy</Disease_Name>
      <Disease_Detail>Fibrocalculous Pancreatopathy</Disease_Detail>
      <Disease_DB>FBR065</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fibrocalculous_pancreatopathy?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diabetic Ketoacidosis</Disease_Name>
      <Disease_Detail>Diabetic Ketoacidosis</Disease_Detail>
      <Disease_DB>DBT001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetic_ketoacidosis?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Granulosa Cell Tumor of the Ovary</Disease_Name>
      <Disease_Detail>Granulosa Cell Tumor of the Ovary</Disease_Detail>
      <Disease_DB>GRN022</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/granulosa_cell_tumor_of_the_ovary?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fetal Macrosomia</Disease_Name>
      <Disease_Detail>Fetal Macrosomia</Disease_Detail>
      <Disease_DB>FTL021</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fetal_macrosomia?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypersomnia</Disease_Name>
      <Disease_Detail>Hypersomnia</Disease_Detail>
      <Disease_DB>HYP263</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypersomnia?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Stiff-Person Syndrome</Disease_Name>
      <Disease_Detail>Stiff-Person Syndrome</Disease_Detail>
      <Disease_DB>STF001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/stiff_person_syndrome?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Alopecia Universalis</Disease_Name>
      <Disease_Detail>Alopecia Universalis</Disease_Detail>
      <Disease_DB>ALP001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/alopecia_universalis?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Type 2 Diabetes Mellitus</Disease_Name>
      <Disease_Detail>Diabetes Mellitus</Disease_Detail>
      <Disease_DB>TYP009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/type_2_diabetes_mellitus?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Necrotizing Fasciitis</Disease_Name>
      <Disease_Detail>Necrotizing Fasciitis</Disease_Detail>
      <Disease_DB>NCR007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/necrotizing_fasciitis?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>End Stage Renal Failure</Disease_Name>
      <Disease_Detail>End Stage Renal Failure</Disease_Detail>
      <Disease_DB>END030</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/end_stage_renal_failure?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lipoid Proteinosis</Disease_Name>
      <Disease_Detail>Lipoid Proteinosis</Disease_Detail>
      <Disease_DB>LPD006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lipoid_proteinosis?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pancreatic Islet Cell Tumors</Disease_Name>
      <Disease_Detail>Pancreatic Cancer</Disease_Detail>
      <Disease_DB>PNC053</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pancreatic_islet_cell_tumors?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Calciphylaxis</Disease_Name>
      <Disease_Detail>Calciphylaxis</Disease_Detail>
      <Disease_DB>CLC001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/calciphylaxis?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Maturity-Onset Diabetes of the Young, Type 1</Disease_Name>
      <Disease_Detail>Maturity-Onset Diabetes of the Young</Disease_Detail>
      <Disease_DB>MTR018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/maturity_onset_diabetes_of_the_young_type_1?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Congenital Generalized Lipodystrophy</Disease_Name>
      <Disease_Detail>Congenital Generalized Lipodystrophy</Disease_Detail>
      <Disease_DB>CNG012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/congenital_generalized_lipodystrophy?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Metabolic Syndrome X</Disease_Name>
      <Disease_Detail>Metabolic Syndrome X</Disease_Detail>
      <Disease_DB>MTB001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/metabolic_syndrome_x?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypoglycemic Coma</Disease_Name>
      <Disease_Detail>Hypoglycemic Coma</Disease_Detail>
      <Disease_DB>HYP026</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypoglycemic_coma?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Autoimmune Polyendocrine Syndrome Type 2</Disease_Name>
      <Disease_Detail>Autoimmune Polyendocrine Syndrome</Disease_Detail>
      <Disease_DB>ATM001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/autoimmune_polyendocrine_syndrome_type_2?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hair-an Syndrome</Disease_Name>
      <Disease_Detail>Hair-an Syndrome</Disease_Detail>
      <Disease_DB>HRN019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hair_an_syndrome?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Hyperinsulinism</Disease_Name>
      <Disease_Detail>Familial Hyperinsulinism</Disease_Detail>
      <Disease_DB>FML184</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_hyperinsulinism?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Autoimmune Polyglandular Syndrome Type 2</Disease_Name>
      <Disease_Detail>Autoimmune Polyendocrine Syndrome</Disease_Detail>
      <Disease_DB>ATM025</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/autoimmune_polyglandular_syndrome_type_2?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Postural Hypotension</Disease_Name>
      <Disease_Detail>Postural Hypotension</Disease_Detail>
      <Disease_DB>PST055</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/postural_hypotension?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gas Gangrene</Disease_Name>
      <Disease_Detail>Gas Gangrene</Disease_Detail>
      <Disease_DB>GSG001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gas_gangrene?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Maturity-Onset Diabetes of the Young, Type 10</Disease_Name>
      <Disease_Detail>Maturity-Onset Diabetes of the Young</Disease_Detail>
      <Disease_DB>MTR044</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/maturity_onset_diabetes_of_the_young_type_10?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Skin Tag</Disease_Name>
      <Disease_Detail>Skin Tag</Disease_Detail>
      <Disease_DB>SKN023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/skin_tag?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Donohue Syndrome</Disease_Name>
      <Disease_Detail>Donohue Syndrome</Disease_Detail>
      <Disease_DB>DNH001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/donohue_syndrome?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diabetic Angiopathy</Disease_Name>
      <Disease_Detail>Diabetic Angiopathy</Disease_Detail>
      <Disease_DB>DBT008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetic_angiopathy?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Aromatase Deficiency</Disease_Name>
      <Disease_Detail>Aromatase Deficiency</Disease_Detail>
      <Disease_DB>ARM001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/aromatase_deficiency?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypokalemic Periodic Paralysis</Disease_Name>
      <Disease_Detail>Hypokalemic Periodic Paralysis</Disease_Detail>
      <Disease_DB>HYP051</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypokalemic_periodic_paralysis?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lipodystrophy</Disease_Name>
      <Disease_Detail>Lipodystrophy</Disease_Detail>
      <Disease_DB>LPD010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lipodystrophy?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Adrenocortical Insufficiency</Disease_Name>
      <Disease_Detail>Adrenocortical Insufficiency</Disease_Detail>
      <Disease_DB>ADR027</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/adrenocortical_insufficiency?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pituitary Apoplexy</Disease_Name>
      <Disease_Detail>Pituitary Apoplexy</Disease_Detail>
      <Disease_DB>PTT004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pituitary_apoplexy?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Rabson-Mendenhall Syndrome</Disease_Name>
      <Disease_Detail>Rabson-Mendenhall Syndrome</Disease_Detail>
      <Disease_DB>RBS003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/rabson_mendenhall_syndrome?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acrodysostosis</Disease_Name>
      <Disease_Detail>Acrodysostosis</Disease_Detail>
      <Disease_DB>ACR013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acrodysostosis?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hyperinsulinism</Disease_Name>
      <Disease_Detail>Hyperinsulinism</Disease_Detail>
      <Disease_DB>HYP060</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hyperinsulinism?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Insulin Resistance</Disease_Name>
      <Disease_Detail>Insulin Resistance</Disease_Detail>
      <Disease_DB>INS005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/insulin_resistance?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fascioliasis</Disease_Name>
      <Disease_Detail>Fascioliasis</Disease_Detail>
      <Disease_DB>FSC002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fascioliasis?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pancreatic Agenesis</Disease_Name>
      <Disease_Detail>Pancreatic Agenesis</Disease_Detail>
      <Disease_DB>PNC045</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pancreatic_agenesis?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Adult Dermatomyositis</Disease_Name>
      <Disease_Detail>Adult Dermatomyositis</Disease_Detail>
      <Disease_DB>ADL027</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/adult_dermatomyositis?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Monogenic Diabetes</Disease_Name>
      <Disease_Detail>Monogenic Diabetes</Disease_Detail>
      <Disease_DB>MNG006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/monogenic_diabetes?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Mandibuloacral Dysplasia</Disease_Name>
      <Disease_Detail>Mandibuloacral Dysplasia</Disease_Detail>
      <Disease_DB>MND007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/mandibuloacral_dysplasia?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Sexual Disorder</Disease_Name>
      <Disease_Detail>Sexual Disorder</Disease_Detail>
      <Disease_DB>SXL003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/sexual_disorder?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Permanent Neonatal Diabetes Mellitus</Disease_Name>
      <Disease_Detail>Permanent Neonatal Diabetes Mellitus</Disease_Detail>
      <Disease_DB>PRM030</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/permanent_neonatal_diabetes_mellitus?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Megalencephaly</Disease_Name>
      <Disease_Detail>Megalencephaly</Disease_Detail>
      <Disease_DB>MGL013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/megalencephaly?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Morbid Obesity</Disease_Name>
      <Disease_Detail>Morbid Obesity</Disease_Detail>
      <Disease_DB>MRB003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/morbid_obesity?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acquired Generalized Lipodystrophy</Disease_Name>
      <Disease_Detail>Acquired Generalized Lipodystrophy</Disease_Detail>
      <Disease_DB>ACQ022</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acquired_generalized_lipodystrophy?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diabetic Macular Edema</Disease_Name>
      <Disease_Detail>Diabetic Macular Edema</Disease_Detail>
      <Disease_DB>DBT006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetic_macular_edema?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Carotid Intimal Medial Thickness</Disease_Name>
      <Disease_Detail>Carotid Intimal Medial Thickness</Disease_Detail>
      <Disease_DB>CRT018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/carotid_intimal_medial_thickness?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Maturity-Onset Diabetes of the Young</Disease_Name>
      <Disease_Detail>Maturity-Onset Diabetes of the Young</Disease_Detail>
      <Disease_DB>MTR004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/maturity_onset_diabetes_of_the_young?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypothalamic Hamartomas</Disease_Name>
      <Disease_Detail>Hypothalamic Hamartomas</Disease_Detail>
      <Disease_DB>HYP231</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypothalamic_hamartomas?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diabetic Autonomic Neuropathy</Disease_Name>
      <Disease_Detail>Diabetic Autonomic Neuropathy</Disease_Detail>
      <Disease_DB>DBT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetic_autonomic_neuropathy?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Necrobiosis Lipoidica</Disease_Name>
      <Disease_Detail>Necrobiosis Lipoidica</Disease_Detail>
      <Disease_DB>NCR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/necrobiosis_lipoidica?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Essential Hypertension</Disease_Name>
      <Disease_Detail>Essential Hypertension</Disease_Detail>
      <Disease_DB>ESS002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/essential_hypertension?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Type 1 Diabetes Mellitus</Disease_Name>
      <Disease_Detail>Diabetes Mellitus</Disease_Detail>
      <Disease_DB>TYP008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/type_1_diabetes_mellitus?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Brittle Diabetes</Disease_Name>
      <Disease_Detail>Brittle Diabetes</Disease_Detail>
      <Disease_DB>BRT037</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/brittle_diabetes?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lipid Metabolism Disorder</Disease_Name>
      <Disease_Detail>Lipid Metabolism Disorder</Disease_Detail>
      <Disease_DB>LPD008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lipid_metabolism_disorder?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Duodenitis</Disease_Name>
      <Disease_Detail>Duodenitis</Disease_Detail>
      <Disease_DB>DDN006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/duodenitis?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diabetes Mellitus</Disease_Name>
      <Disease_Detail>Diabetes Mellitus</Disease_Detail>
      <Disease_DB>DBT009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetes_mellitus?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hyporeninemic Hypoaldosteronism</Disease_Name>
      <Disease_Detail>Hyporeninemic Hypoaldosteronism</Disease_Detail>
      <Disease_DB>HYP226</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hyporeninemic_hypoaldosteronism?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acute Insulin Response</Disease_Name>
      <Disease_Detail>Acute Insulin Response</Disease_Detail>
      <Disease_DB>ACT088</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acute_insulin_response?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Berardinelli-Seip Congenital Lipodystrophy</Disease_Name>
      <Disease_Detail>Berardinelli-Seip Congenital Lipodystrophy</Disease_Detail>
      <Disease_DB>BRR012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/berardinelli_seip_congenital_lipodystrophy?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ins-Related Permanent Neonatal Diabetes Mellitus</Disease_Name>
      <Disease_Detail>Ins-Related Permanent Neonatal Diabetes Mellitus</Disease_Detail>
      <Disease_DB>INS012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ins_related_permanent_neonatal_diabetes_mellitus?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Empty Sella Syndrome</Disease_Name>
      <Disease_Detail>Empty Sella Syndrome</Disease_Detail>
      <Disease_DB>EMP001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/empty_sella_syndrome?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fasting Hypoglycemia</Disease_Name>
      <Disease_Detail>Fasting Hypoglycemia</Disease_Detail>
      <Disease_DB>FST010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fasting_hypoglycemia?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Short Syndrome</Disease_Name>
      <Disease_Detail>Short Syndrome</Disease_Detail>
      <Disease_DB>SHR029</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/short_syndrome?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diabetes Mellitus, Permanent Neonatal, with Neurologic Features</Disease_Name>
      <Disease_Detail>Diabetes Mellitus</Disease_Detail>
      <Disease_DB>DBT043</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetes_mellitus_permanent_neonatal_with_neurologic_features?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Carbohydrate Metabolic Disorder</Disease_Name>
      <Disease_Detail>Carbohydrate Metabolic Disorder</Disease_Detail>
      <Disease_DB>CRB025</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/carbohydrate_metabolic_disorder?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diabetes Mellitus, Insulin-Dependent, 2</Disease_Name>
      <Disease_Detail>Diabetes Mellitus</Disease_Detail>
      <Disease_DB>DBT040</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetes_mellitus_insulin_dependent_2?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Maturity-Onset Diabetes of the Young Type10</Disease_Name>
      <Disease_Detail>Maturity-Onset Diabetes of the Young</Disease_Detail>
      <Disease_DB>MTR048</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/maturity_onset_diabetes_of_the_young_type10?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Combined Hyperlipidemia</Disease_Name>
      <Disease_Detail>Familial Combined Hyperlipidemia</Disease_Detail>
      <Disease_DB>FML020</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_combined_hyperlipidemia?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Spinal Stenosis</Disease_Name>
      <Disease_Detail>Spinal Stenosis</Disease_Detail>
      <Disease_DB>SPN027</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/spinal_stenosis?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hyperglycemia</Disease_Name>
      <Disease_Detail>Hyperglycemia</Disease_Detail>
      <Disease_DB>HYP066</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hyperglycemia?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Renovascular Hypertension</Disease_Name>
      <Disease_Detail>Renovascular Hypertension</Disease_Detail>
      <Disease_DB>RNV001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/renovascular_hypertension?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Biliary Tract Disease</Disease_Name>
      <Disease_Detail>Biliary Tract Disease</Disease_Detail>
      <Disease_DB>BLR006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/biliary_tract_disease?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Laron Syndrome</Disease_Name>
      <Disease_Detail>Laron Syndrome</Disease_Detail>
      <Disease_DB>LRN002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/laron_syndrome?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dumping Syndrome</Disease_Name>
      <Disease_Detail>Dumping Syndrome</Disease_Detail>
      <Disease_DB>DMP001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dumping_syndrome?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypoglycemia</Disease_Name>
      <Disease_Detail>Hypoglycemia</Disease_Detail>
      <Disease_DB>HYP056</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypoglycemia?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fibrocalculous Pancreatic Diabetes</Disease_Name>
      <Disease_Detail>Fibrocalculous Pancreatic Diabetes</Disease_Detail>
      <Disease_DB>FBR063</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fibrocalculous_pancreatic_diabetes?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gallbladder Disease</Disease_Name>
      <Disease_Detail>Gallbladder Disease</Disease_Detail>
      <Disease_DB>GLL020</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gallbladder_disease?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Alstrom Syndrome</Disease_Name>
      <Disease_Detail>Alstrom Syndrome</Disease_Detail>
      <Disease_DB>ALS001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/alstrom_syndrome?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Neonatal Diabetes Mellitus</Disease_Name>
      <Disease_Detail>Neonatal Diabetes Mellitus</Disease_Detail>
      <Disease_DB>NNT009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/neonatal_diabetes_mellitus?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Transient Neonatal Diabetes Mellitus</Disease_Name>
      <Disease_Detail>Transient Neonatal Diabetes Mellitus</Disease_Detail>
      <Disease_DB>TRN032</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/transient_neonatal_diabetes_mellitus?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Aortic Valve Disease</Disease_Name>
      <Disease_Detail>Aortic Disease</Disease_Detail>
      <Disease_DB>ART070</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/aortic_valve_disease?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acanthosis Nigricans</Disease_Name>
      <Disease_Detail>Acanthosis Nigricans</Disease_Detail>
      <Disease_DB>ACN002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acanthosis_nigricans?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Medullary Sponge Kidney</Disease_Name>
      <Disease_Detail>Medullary Sponge Kidney</Disease_Detail>
      <Disease_DB>MDL009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/medullary_sponge_kidney?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Hypertension</Disease_Name>
      <Disease_Detail>Familial Hypertension</Disease_Detail>
      <Disease_DB>FML187</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_hypertension?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Endogenous Depression</Disease_Name>
      <Disease_Detail>Endogenous Depression</Disease_Detail>
      <Disease_DB>END040</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/endogenous_depression?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Overnutrition</Disease_Name>
      <Disease_Detail>Overnutrition</Disease_Detail>
      <Disease_DB>OVR063</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/overnutrition?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Partial Lipodystrophy</Disease_Name>
      <Disease_Detail>Familial Partial Lipodystrophy</Disease_Detail>
      <Disease_DB>FML012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_partial_lipodystrophy?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Autoimmune Polyendocrine Syndrome</Disease_Name>
      <Disease_Detail>Autoimmune Polyendocrine Syndrome</Disease_Detail>
      <Disease_DB>ATM019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/autoimmune_polyendocrine_syndrome?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Johanson-Blizzard Syndrome</Disease_Name>
      <Disease_Detail>Johanson-Blizzard Syndrome</Disease_Detail>
      <Disease_DB>JHN001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/johanson_blizzard_syndrome?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Glucose Intolerance</Disease_Name>
      <Disease_Detail>Glucose Intolerance</Disease_Detail>
      <Disease_DB>GLC003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/glucose_intolerance?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Hyperlipidemia</Disease_Name>
      <Disease_Detail>Familial Hyperlipidemia</Disease_Detail>
      <Disease_DB>FML035</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_hyperlipidemia?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lipoatrophic Diabetes</Disease_Name>
      <Disease_Detail>Lipoatrophic Diabetes</Disease_Detail>
      <Disease_DB>LPT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lipoatrophic_diabetes?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypertension</Disease_Name>
      <Disease_Detail>Hypertension</Disease_Detail>
      <Disease_DB>HYP075</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypertension?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hyperproinsulinemia, Familial, with or Without Diabetes</Disease_Name>
      <Disease_Detail>Hyperproinsulinemia</Disease_Detail>
      <Disease_DB>HYP325</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hyperproinsulinemia_familial_with_or_without_diabetes?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Polycystic Ovary Syndrome</Disease_Name>
      <Disease_Detail>Polycystic Ovary Syndrome</Disease_Detail>
      <Disease_DB>PLY011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/polycystic_ovary_syndrome?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hyperproinsulinemia, Familial</Disease_Name>
      <Disease_Detail>Hyperproinsulinemia</Disease_Detail>
      <Disease_DB>HYP512</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hyperproinsulinemia_familial?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Insulin Autoimmune Syndrome</Disease_Name>
      <Disease_Detail>Insulin Autoimmune Syndrome</Disease_Detail>
      <Disease_DB>INS006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/insulin_autoimmune_syndrome?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Maternally Inherited Diabetes and Deafness</Disease_Name>
      <Disease_Detail>Maternally Inherited Diabetes and Deafness</Disease_Detail>
      <Disease_DB>MTR046</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/maternally_inherited_diabetes_and_deafness?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gestational Diabetes</Disease_Name>
      <Disease_Detail>Gestational Diabetes</Disease_Detail>
      <Disease_DB>GST033</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gestational_diabetes?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypoaldosteronism</Disease_Name>
      <Disease_Detail>Hypoaldosteronism</Disease_Detail>
      <Disease_DB>HYP120</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypoaldosteronism?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ovarian Disease</Disease_Name>
      <Disease_Detail>Ovarian Disease</Disease_Detail>
      <Disease_DB>OVR049</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ovarian_disease?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>3-Hydroxyacyl-Coa Dehydrogenase Deficiency</Disease_Name>
      <Disease_Detail>3-Hydroxyacyl-Coa Dehydrogenase Deficiency</Disease_Detail>
      <Disease_DB>3HY005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/3_hydroxyacyl_coa_dehydrogenase_deficiency?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Neurogenic Hypertension</Disease_Name>
      <Disease_Detail>Neurogenic Hypertension</Disease_Detail>
      <Disease_DB>NRG005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/neurogenic_hypertension?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Nonalcoholic Steatohepatitis</Disease_Name>
      <Disease_Detail>Nonalcoholic Steatohepatitis</Disease_Detail>
      <Disease_DB>NNL002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/nonalcoholic_steatohepatitis?search=INS#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Silent Myocardial Infarction</Disease_Name>
      <Disease_Detail>Silent Myocardial Infarction</Disease_Detail>
      <Disease_DB>SLN001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/silent_myocardial_infarction?search=INS#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>MINI-PROINSULIN, TWO CHAIN INSULIN ANALOG MUTANT: DES B30, HIS(B 10)ASP, PRO(B 28)ASP, NMR, 20 STRUCTURES</PDB_Title>
      <PDB_ID>1SJT</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SJT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Mini-proinsulin and mini-IGF-I: homologous protein sequences encoding non-homologous structures.</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>J.Mol.Biol.(1998)277:103-118</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9514738?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>R6 HUMAN INSULIN HEXAMER (NON-SYMMETRIC), NMR, 10 STRUCTURES</PDB_Title>
      <PDB_ID>1AI0</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AI0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structures of the R6 human insulin hexamer.</PubMed_Title>
      <Author>Chang, X., et al.</Author>
      <Journal>Biochemistry(1997)36:9409-9422</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9235985?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Diabetes-Associated Mutations in Human Insulin: Crystal Structure and Photo-Cross-Linking Studies of A-Chain Variant Insulin Wakayama</PDB_Title>
      <PDB_ID>1XW7</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1XW7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Diabetes-associated mutations in human insulin: crystal structure and photo-cross-linking studies of a-chain variant insulin wakayama</PubMed_Title>
      <Author>Wan, Z.L., et al.</Author>
      <Journal>Biochemistry(2005)44:5000-5016</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15794638?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of MN human arg-insulin</PDB_Title>
      <PDB_ID>2R34</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2R34</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Metal induced structural changes observed in hexameric insulin</PubMed_Title>
      <Author>Sreekanth, R., et al.</Author>
      <Journal>Int.J.Biol.Macromol.(2009)44:29-36</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18977386?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of the rhombohedral form of the M-cresol/insulin R6 hexamer</PDB_Title>
      <PDB_ID>1EV3</PDB_ID>
      <Resolution>1.78</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1EV3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>R6 hexameric insulin complexed with m-cresol or resorcinol.</PubMed_Title>
      <Author>Smith, G.D., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2000)56:1541-1548</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11092919?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR</PDB_Title>
      <PDB_ID>1QJ0</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1QJ0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Consequences of the B5 Histidine --&gt; Tyrosine Mutation in Human Insulin Characterized by X-Ray Crystallography and Conformational Analysis.</PubMed_Title>
      <Author>Tang, L., et al.</Author>
      <Journal>Biochemistry(1999)38:12041</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10508408?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 20 STRUCTURES</PDB_Title>
      <PDB_ID>2AIY</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2AIY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Unraveling the symmetry ambiguity in a hexamer: calculation of the R6 human insulin structure.</PubMed_Title>
      <Author>O'Donoghue, S.I., et al.</Author>
      <Journal>J.Biomol.NMR(2000)16:93-108</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10723989?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, REFINED AVERAGE STRUCTURE</PDB_Title>
      <PDB_ID>3AIY</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3AIY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Unraveling the symmetry ambiguity in a hexamer: calculation of the R6 human insulin structure.</PubMed_Title>
      <Author>ODonoghue, S.I., et al.</Author>
      <Journal>J.Biomol.NMR(2000)16:93-108</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10723989?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Dynamics of insulin probed by 1H-NMR amide proton exchange anomalous flexibility of the receptor-binding surface</PDB_Title>
      <PDB_ID>2KJJ</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2KJJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Dynamics of Insulin Probed by 1H-NMR Amide Proton E Anomalous Flexibility of the Receptor-Binding Surfa</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human insulin with Ni+2 complex</PDB_Title>
      <PDB_ID>3INC</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3INC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Metal induced conformational changes in human insulin: Crystal structures of Sr+2, Ni+2 and Cu+2 complexes of human insulin</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>THREE-DIMENSIONAL SOLUTION STRUCTURE OF AN INSULIN DIMER. A STUDY OF THE B9(ASP) MUTANT OF HUMAN INSULIN USING NUCLEAR MAGNETIC RESONANCE DISTANCE GEOMETRY AND RESTRAINED MOLECULAR DYNAMICS</PDB_Title>
      <PDB_ID>1MHI</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MHI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Three-dimensional solution structure of an insulin dimer. A study of the B9(Asp) mutant of human insulin using nuclear magnetic resonance, distance geometry and restrained molecular dynamics.</PubMed_Title>
      <Author>Jorgensen, A.M., et al.</Author>
      <Journal>J.Mol.Biol.(1992)227:1146-1163</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/1433291?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human insulin cocrystallized with protamine and urea</PDB_Title>
      <PDB_ID>2OMG</PDB_ID>
      <Resolution>1.52</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OMG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural characterization of insulin NPH formulations.</PubMed_Title>
      <Author>Norrman, M., et al.</Author>
      <Journal>EUR.J.PHARM.SCI.(2007)30:414-423</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17339105?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE-A2-ALA, HIS-B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES</PDB_Title>
      <PDB_ID>1K3M</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1K3M</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A cavity-forming mutation in insulin induces segmental unfolding of a surrounding alpha-helix.</PubMed_Title>
      <Author>Xu, B., et al.</Author>
      <Journal>Protein Sci.(2002)11:104-116</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11742127?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Semi-synthetic analogue of human insulin NMeTyrB26-insulin in monomer form</PDB_Title>
      <PDB_ID>2WS1</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2WS1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Implications for the Active Form of Human Insulin Based on the Structural Convergence of Highly Active Hormone Analogues.</PubMed_Title>
      <Author>Jiracek, J., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2010)107:1966</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20133841?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Dehydrated T6 human insulin at 100 K</PDB_Title>
      <PDB_ID>1OS3</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OS3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Lessons from an aged, dried crystal of T(6) human insulin.</PubMed_Title>
      <Author>Smith, G.D., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2003)59:1384-1394</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12876340?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR structure of human insulin monomer in 35% CD3CN zinc free, 50 structures</PDB_Title>
      <PDB_ID>2JV1</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2JV1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of human insulin monomer in water/acetonitrile solution.</PubMed_Title>
      <Author>Bocian, W., et al.</Author>
      <Journal>J.Biomol.Nmr(2008)40:55-64</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18040865?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE FORM ULTALENTE INSULIN MICROCRYSTALS</PDB_Title>
      <PDB_ID>2VJZ</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2VJZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of Ultralente-A Microcrystalline Insulin Suspension.</PubMed_Title>
      <Author>Wagner, A., et al.</Author>
      <Journal>Proteins(2009)74:1018</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18767151?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>INSULIN MUTANT A3 GLY,(B1, B10, B16, B27)GLU, DES-B30, NMR, 19 STRUCTURES</PDB_Title>
      <PDB_ID>1IOG</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IOG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The relationship between insulin bioactivity and structure in the NH2-terminal A-chain helix.</PubMed_Title>
      <Author>Olsen, H.B., et al.</Author>
      <Journal>J.Mol.Biol.(1998)284:477-488</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9813131?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE-A2-GLY, VAL-A3-GLY, HIS-B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 20 STRUCTURES</PDB_Title>
      <PDB_ID>1LKQ</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1LKQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Mechanism of insulin chain combination. Asymmetric roles of A-chain alpha-helices in disulfide pairing</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>J.Biol.Chem.(2002)277:43443-43453</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12196530?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Insulin in Complex with Sulfatide</PDB_Title>
      <PDB_ID>3BRR</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BRR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Insulin co-crystallizes with its beta-cell chaperone sulfatide</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Receptor binding redefined by a structural switch in a mutant Human Insulin</PDB_Title>
      <PDB_ID>1HIT</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HIT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Receptor binding redefined by a structural switch in a mutant human insulin.</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>Nature(1991)354:238-241</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/1961250?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Solution Structure of Human Proinsulin C-Peptide</PDB_Title>
      <PDB_ID>1T0C</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1T0C</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structure of human proinsulin C-peptide</PubMed_Title>
      <Author>Munte, C.E., et al.</Author>
      <Journal>Febs J.(2005)272:4284-4293</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16098208?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE FORM ULTALENTE INSULIN MICROCRYSTALS</PDB_Title>
      <PDB_ID>2VK0</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2VK0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of Ultralente--A Microcrystalline Insulin Suspension.</PubMed_Title>
      <Author>Wagner, A., et al.</Author>
      <Journal>Proteins(2009)74:1018</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18767151?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Dehydrated T6 human insulin at 295 K</PDB_Title>
      <PDB_ID>1OS4</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OS4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Lessons from an aged, dried crystal of T(6) human insulin.</PubMed_Title>
      <Author>Smith, G.D., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2003)59:1384-1394</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12876340?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS-B10-ASP, VAL-B12-ALA, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES</PDB_Title>
      <PDB_ID>1T1K</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1T1K</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>How Insulin Binds: the B-Chain alpha-Helix Contacts the L1 beta-Helix of the Insulin Receptor.</PubMed_Title>
      <Author>Huang, K., et al.</Author>
      <Journal>J.Mol.Biol.(2004)341:529-550</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15276842?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>INSULINE(1SEC) AND UV LASER EXCITED FLUORESCENCE</PDB_Title>
      <PDB_ID>2C8Q</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2C8Q</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Uv Laser-Excited Fluorescence as a Tool for the Visualization of Protein Crystals Mounted in Loops.</PubMed_Title>
      <Author>Vernede, X., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2006)62:253</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16510972?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human insulin in complex with cucurbit[7]uril</PDB_Title>
      <PDB_ID>3Q6E</PDB_ID>
      <Resolution>2.05</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3Q6E</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular recognition of insulin by a synthetic receptor.</PubMed_Title>
      <Author>Chinai, J.M., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2011)133:8810-8813</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21473587?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human insulin cocrystallized with ARG-12 peptide in presence of urea</PDB_Title>
      <PDB_ID>2OMH</PDB_ID>
      <Resolution>1.36</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OMH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural characterization of insulin NPH formulations.</PubMed_Title>
      <Author>Norrman, M., et al.</Author>
      <Journal>EUR.J.PHARM.SCI.(2007)30:414-423</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17339105?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS-B10-ASP, VAL-B12-ABA, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES</PDB_Title>
      <PDB_ID>1T1Q</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1T1Q</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>How Insulin Binds: the B-Chain alpha-Helix Contacts the L1 beta-Helix of the Insulin Receptor.</PubMed_Title>
      <Author>Huang, K., et al.</Author>
      <Journal>J.Mol.Biol.(2004)341:529-550</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15276842?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>DESPENTAPEPTIDE INSULIN IN ACETIC ACID (PH 2)</PDB_Title>
      <PDB_ID>2CEU</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2CEU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>I222 Crystal Form of Despentapeptide (B26-B30) Insulin Provides New Insights Into the Properties of Monomeric Insulin.</PubMed_Title>
      <Author>Whittingham, J.L., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2006)62:505</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16627943?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human insulin</PDB_Title>
      <PDB_ID>3E7Z</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3E7Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of human insulin</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>TYRB25,NMEPHEB26,LYSB28,PROB29-INSULIN ANALOGUE CRYSTAL STRUCTURE</PDB_Title>
      <PDB_ID>3ZS2</PDB_ID>
      <Resolution>1.97</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ZS2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Non-Equivalent Role of Inter- and Intramolecular Hydrogen Bonds in the Insulin Dimer Interface.</PubMed_Title>
      <Author>Antolikova, E., et al.</Author>
      <Journal>J.Biol.Chem.(2011)286:36968</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21880708?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR Structure of human insulin mutant GLY-B20-D-ALA, GLY-B23-D-ALA PRO-B28-LYS, LYS-B29-PRO, 20 Structures</PDB_Title>
      <PDB_ID>2L1Y</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2L1Y</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Chiral Protein Engineering and its Application in G Health</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>T6 Human Insulin at 1.0 A Resolution</PDB_Title>
      <PDB_ID>1MSO</PDB_ID>
      <Resolution>1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MSO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structure of T6 human insulin at 1.0 A resolution.</PubMed_Title>
      <Author>Smith, G.D., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2003)59:474-482</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12595704?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>allo-ThrA3 DKP-insulin</PDB_Title>
      <PDB_ID>2JUU</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2JUU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The A-chain of Insulin Contacts the Insert Domain of the Insulin Receptor: PHOTO-CROSS-LINKING AND MUTAGENESIS OF A DIABETES-RELATED CREVICE.</PubMed_Title>
      <Author>Huang, K., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:35337-35349</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17884811?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>INSULIN MUTANT (B1, B10, B16, B27)GLU, DES-B30, NMR, 25 STRUCTURES</PDB_Title>
      <PDB_ID>1HUI</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HUI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structure of an engineered insulin monomer at neutral pH.</PubMed_Title>
      <Author>Olsen, H.B., et al.</Author>
      <Journal>Biochemistry(1996)35:8836-8845</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8688419?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of Human Arg-Insulin</PDB_Title>
      <PDB_ID>2QIU</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2QIU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural interpretation of reduced insulin activity as seen in the crystal structure of human Arg-insulin</PubMed_Title>
      <Author>Sreekanth, R., et al.</Author>
      <Journal>Biochimie(2008)90:467-473</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18029081?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR STRUCTURE OF THE HUMAN INSULIN-HIS(B16)</PDB_Title>
      <PDB_ID>1HLS</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HLS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>High-resolution structure of an engineered biologically potent insulin monomer, B16 Tyr--&gt;His, as determined by nuclear magnetic resonance spectroscopy.</PubMed_Title>
      <Author>Ludvigsen, S., et al.</Author>
      <Journal>Biochemistry(1994)33:7998-8006</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8025104?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human HLA-A*0201-ALWGPDPAAA</PDB_Title>
      <PDB_ID>3UTQ</PDB_ID>
      <Resolution>1.67</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3UTQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes.</PubMed_Title>
      <Author>Bulek, A.M., et al.</Author>
      <Journal>Nat.Immunol.(2012)13:283-289</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22245737?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of humnan insulin Sr+2 complex</PDB_Title>
      <PDB_ID>3ILG</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ILG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Metal induced conformational changes in human insulin: Crystal structures of Sr+2, Ni+2 and Cu+2 complexes of human insulin</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>crystal structure of human insulin-degrading enzyme in complex with insulin B chain</PDB_Title>
      <PDB_ID>2G56</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2G56</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism.</PubMed_Title>
      <Author>Shen, Y., et al.</Author>
      <Journal>Nature(2006)443:870-874</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17051221?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>INSULIN AT PH 2: STRUCTURAL ANALYSIS OF THE CONDITIONS PROMOTING INSULIN FIBRE FORMATION.</PDB_Title>
      <PDB_ID>1GUJ</PDB_ID>
      <Resolution>1.62</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GUJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Insulin at Ph2: Structural Analysis of the Conditions Promoting Insulin Fibre Formation</PubMed_Title>
      <Author>Whittingham, J.L., et al.</Author>
      <Journal>J.Mol.Biol.(2002)318:479</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12051853?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER</PDB_Title>
      <PDB_ID>1TRZ</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TRZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic evidence for dual coordination around zinc in the T3R3 human insulin hexamer.</PubMed_Title>
      <Author>Ciszak, E., et al.</Author>
      <Journal>Biochemistry(1994)33:1512-1517</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8312271?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE-A2-ALLO-ILE, HIS-B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES</PDB_Title>
      <PDB_ID>1KMF</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1KMF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Chiral mutagenesis of insulin's hidden receptor-binding surface: structure of an allo-isoleucine(A2) analogue.</PubMed_Title>
      <Author>Xu, B., et al.</Author>
      <Journal>J.Mol.Biol.(2002)316:435-441</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11866509?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>PARADOXICAL STRUCTURE AND FUNCTION IN A MUTANT HUMAN INSULIN ASSOCIATED WITH DIABETES MELLITUS</PDB_Title>
      <PDB_ID>1HIQ</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HIQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Paradoxical structure and function in a mutant human insulin associated with diabetes mellitus.</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1993)90:582-586</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8421693?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>INSULINE(60SEC) AND UV LASER EXCITED FLUORESCENCE</PDB_Title>
      <PDB_ID>2C8R</PDB_ID>
      <Resolution>1.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2C8R</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Uv Laser-Excited Fluorescence as a Tool for the Visualization of Protein Crystals Mounted in Loops.</PubMed_Title>
      <Author>Vernede, X., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2006)62:253</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16510972?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications</PDB_Title>
      <PDB_ID>3FQ9</PDB_ID>
      <Resolution>1.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FQ9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design of an insulin analog with enhanced receptor binding selectivity: rationale, structure, and therapeutic implications.</PubMed_Title>
      <Author>Zhao, M., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:32178-32187</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19773552?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>1.3 A STRUCTURE OF T3R3 HUMAN INSULIN AT 100 K</PDB_Title>
      <PDB_ID>1G7B</PDB_ID>
      <Resolution>1.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1G7B</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Phase changes in T(3)R(3)(f) human insulin: temperature or pressure induced?</PubMed_Title>
      <Author>Smith, G.D., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2001)57:1091-1100</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11468392?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE</PDB_Title>
      <PDB_ID>1TYL</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TYL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structure of a complex of hexameric insulin and 4'-hydroxyacetanilide.</PubMed_Title>
      <Author>Smith, G.D., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1994)91:8851-8855</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8090735?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of the T6 human insulin derivative with nickel at 1.35 A resolution</PDB_Title>
      <PDB_ID>3EXX</PDB_ID>
      <Resolution>1.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EXX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the T6 Human Nickel Insulin Derivative at 1.35 A Resolution.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Zn-bound human insulin-degrading enzyme in complex with insulin B chain</PDB_Title>
      <PDB_ID>2G54</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2G54</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism.</PubMed_Title>
      <Author>Shen, Y., et al.</Author>
      <Journal>Nature(2006)443:870-874</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17051221?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR STRUCTURE OF HUMAN INSULIN under Amyloidogenic Condition, 15 STRUCTURES</PDB_Title>
      <PDB_ID>1SF1</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SF1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Mechanism of insulin fibrillation: the structure of insulin under amyloidogenic conditions resembles a protein-folding intermediate</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>J.Biol.Chem.(2004)279:21449-21460</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14988398?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMEPHEB25 INSULIN ANALOGUE CRYSTAL STRUCTURE</PDB_Title>
      <PDB_ID>3ZQR</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ZQR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Non-Equivalent Role of Inter- and Intramolecular Hydrogen Bonds in the Insulin Dimer Interface.</PubMed_Title>
      <Author>Antolikova, E., et al.</Author>
      <Journal>J.Biol.Chem.(2011)286:36968</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21880708?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Humal Insulin Mutant B31Lys-B32Arg</PDB_Title>
      <PDB_ID>2RN5</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2RN5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>NMR structure of biosynthetic engineered human insulin monomer B31(Lys)-B32(Arg) in water/acetonitrile solution. Comparison with the solution structure of native human insulin monomer</PubMed_Title>
      <Author>Bocian, W., et al.</Author>
      <Journal>Biopolymers(2008)89:820-830</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18491415?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR structure of human insulin mutant gly-b8-d-ala, his-b10-asp, pro-b28-lys, lys-b29-pro, 20 structures</PDB_Title>
      <PDB_ID>2KQQ</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2KQQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure and Dynamics of an Turn-Stabilize But Ina Insulin Analog.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human insulin in presence of urea at pH 6.5</PDB_Title>
      <PDB_ID>2OM0</PDB_ID>
      <Resolution>2.05</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OM0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic characterization of two novel crystal forms of human insulin induced by chaotropic agents and a shift in pH.</PubMed_Title>
      <Author>Norrman, M., et al.</Author>
      <Journal>Bmc Struct.Biol.(2007)7:83-83</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18093308?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>ThrA3-DKP-insulin</PDB_Title>
      <PDB_ID>2JUM</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2JUM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The A-chain of Insulin Contacts the Insert Domain of the Insulin Receptor: PHOTO-CROSS-LINKING AND MUTAGENESIS OF A DIABETES-RELATED CREVICE.</PubMed_Title>
      <Author>Huang, K., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:35337-35349</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17884811?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Semi-synthetic analogue of human insulin NMeAlaB26-insulin at pH 3.0</PDB_Title>
      <PDB_ID>2WRX</PDB_ID>
      <Resolution>1.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2WRX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Implications for the Active Form of Human Insulin Based on the Structural Convergence of Highly Active Hormone Analogues.</PubMed_Title>
      <Author>Jiracek, J., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2010)107:1966</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20133841?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR STRUCTURE OF HUMAN INSULIN IN 20% ACETIC ACID, ZINC-FREE, 10 STRUCTURES</PDB_Title>
      <PDB_ID>2HIU</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HIU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of a protein in a kinetic trap.</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>Nat.Struct.Biol.(1995)2:129-138</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7749917?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of RB human arg-insulin</PDB_Title>
      <PDB_ID>2R35</PDB_ID>
      <Resolution>2.08</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2R35</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Metal induced structural changes observed in hexameric insulin</PubMed_Title>
      <Author>Sreekanth, R., et al.</Author>
      <Journal>Int.J.Biol.Macromol.(2009)44:29-36</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18977386?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 'RED' SUBSTATE, AVERAGE STRUCTURE</PDB_Title>
      <PDB_ID>5AIY</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=5AIY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Unraveling the symmetry ambiguity in a hexamer: calculation of the R6 human insulin structure.</PubMed_Title>
      <Author>ODonoghue, S.I., et al.</Author>
      <Journal>J.Biomol.NMR(2000)16:93-108</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10723989?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FIRST PROTEIN STRUCTURE DETERMINED FROM X-RAY POWDER DIFFRACTION DATA</PDB_Title>
      <PDB_ID>1FUB</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FUB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The first protein crystal structure determined from high-resolution X-ray powder diffraction data: a variant of T3R3 human insulin-zinc complex produced by grinding.</PubMed_Title>
      <Author>Von Dreele, R.B., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2000)56:1549-1553</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11092920?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human insulin in presence of thiocyanate at pH 7.0</PDB_Title>
      <PDB_ID>2OLZ</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OLZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic characterization of two novel crystal forms of human insulin induced by chaotropic agents and a shift in pH.</PubMed_Title>
      <Author>Norrman, M., et al.</Author>
      <Journal>Bmc Struct.Biol.(2007)7:83-83</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18093308?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>MINI-PROINSULIN, SINGLE CHAIN INSULIN ANALOG MUTANT: DES B30, HIS(B 10)ASP, PRO(B 28)ASP AND PEPTIDE BOND BETWEEN LYS B 29 AND GLY A 1, NMR, 20 STRUCTURES</PDB_Title>
      <PDB_ID>1SJU</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SJU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Mini-proinsulin and mini-IGF-I: homologous protein sequences encoding non-homologous structures.</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>J.Mol.Biol.(1998)277:103-118</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9514738?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SEMI-SYNTHETIC HIGHLY ACTIVE ANALOGUE OF HUMAN INSULIN NMEHISB26-DTI-NH2</PDB_Title>
      <PDB_ID>2WRV</PDB_ID>
      <Resolution>2.15</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2WRV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Implications for the Active Form of Human Insulin Based on the Structural Convergence of Highly Active Hormone Analogues.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Structure of the monoclinic form of the M-cresol/insulin R6 hexamer</PDB_Title>
      <PDB_ID>1EV6</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1EV6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>R6 Hexameric Insulin Complexed with m-Cresol or Resorcinol</PubMed_Title>
      <Author>Smith, G.D., et al.</Author>
      <Journal>Biochem.Biophys.Res.Commun.(2000)56:1541-1548</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11092919?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Insulin fibrillation is the Janus face of induced fit. A chiaral clamp stabilizes the native state at the expense of activity</PDB_Title>
      <PDB_ID>3P2X</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3P2X</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Insulin fibrillation is the Janus face of induced fit.  A chiral clamp stabilizes the native state at the expense of activity</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human insulin</PDB_Title>
      <PDB_ID>3E7Y</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3E7Y</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of human insulin</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN INSULIN DEGRADING ENZYME IN COMPLEX WITH IODINATED INSULIN</PDB_Title>
      <PDB_ID>2WC0</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2WC0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular Basis of Catalytic Chamber-Assisted Unfolding and Cleavage of Human Insulin by Human Insulin Degrading Enzyme.</PubMed_Title>
      <Author>Manolopoulou, M., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:14177-14188</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19321446?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR structure of human insulin mutant GLY-B8-SER, HIS-B10-ASP PRO-B28-LYS, LYS-B29-PRO, 20 structures</PDB_Title>
      <PDB_ID>2HHO</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HHO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Toward the Active Conformation of Insulin: Stereospecific modulation of a structural switch in the B chain.</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>J.Biol.Chem.(2006)281:24900-24909</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16762918?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>AbaA3-DKP-insulin</PDB_Title>
      <PDB_ID>2JUV</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2JUV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The A-chain of Insulin Contacts the Insert Domain of the Insulin Receptor: PHOTO-CROSS-LINKING AND MUTAGENESIS OF A DIABETES-RELATED CREVICE.</PubMed_Title>
      <Author>Huang, K., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:35337-35349</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17884811?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Semi-synthetic analogue of human insulin ProB26-DTI in monomer form</PDB_Title>
      <PDB_ID>2WS4</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2WS4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Implications for the Active Form of Human Insulin Based on the Structural Convergence of Highly Active Hormone Analogues.</PubMed_Title>
      <Author>Jiracek, J., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2010)107:1966</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20133841?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Enhancing the Therapeutic Properties of a Protein by a Designed Zinc-Binding Site, Structural principles of a novel long-acting insulin analog</PDB_Title>
      <PDB_ID>3KQ6</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KQ6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Supramolecular protein engineering: design of zinc-stapled insulin hexamers as a long acting depot.</PubMed_Title>
      <Author>Phillips, N.B., et al.</Author>
      <Journal>J.Biol.Chem.(2010)285:11755-11759</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20181952?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Human Insulin complexed with Cu+2 metal ion</PDB_Title>
      <PDB_ID>3IR0</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IR0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Metal induced structural changes observed in Human insulin</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Semi-synthetic analogue of human insulin NMeTyrB26-insulin in hexamer form</PDB_Title>
      <PDB_ID>2WS6</PDB_ID>
      <Resolution>1.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2WS6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Implications for the Active Form of Human Insulin Based on the Structural Convergence of Highly Active Hormone Analogues.</PubMed_Title>
      <Author>Jiracek, J., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2010)107:1966</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20133841?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SEMI-SYNTHETIC ANALOGUE OF HUMAN INSULIN PROB26-DTI</PDB_Title>
      <PDB_ID>2WS7</PDB_ID>
      <Resolution>2.59</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2WS7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Implications for the Active Form of Human Insulin Based on the Structural Convergence of Highly Active Hormone Analogues.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF LYSB29(NEPSILON OMEGA-CARBOXYHEPTADECANOYL) DES(B30) HUMAN INSULIN</PDB_Title>
      <PDB_ID>3ZU1</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ZU1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of Lysb29(Nepsilon Omega-Carboxyheptadecanoyl) Des(B30) Human Insulin</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 10 STRUCTURES</PDB_Title>
      <PDB_ID>1AIY</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AIY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structures of the R6 human insulin hexamer.</PubMed_Title>
      <Author>Chang, X., et al.</Author>
      <Journal>Biochemistry(1997)36:9409-9422</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9235985?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE</PDB_Title>
      <PDB_ID>1BEN</PDB_ID>
      <Resolution>1.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BEN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A novel complex of a phenolic derivative with insulin: structural features related to the T--&gt;R transition.</PubMed_Title>
      <Author>Smith, G.D., et al.</Author>
      <Journal>Protein Sci.(1996)5:1502-1511</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8844841?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURAL PROPERTIES OF THE B25TYR-NME-B26PHE INSULIN MUTANT.</PDB_Title>
      <PDB_ID>1W8P</PDB_ID>
      <Resolution>2.08</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1W8P</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Towards the Insulin-Igf-I Intermediate Structures: Functional and Structural Properties of the B25Tyr-Nme-B26Phe Insulin Mutant.</PubMed_Title>
      <Author>Zarkowa, L., et al.</Author>
      <Journal>Biochemistry(2004)43:16293</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15610023?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SEMI-SYNTHETIC ANALOGUE OF HUMAN INSULIN NMEALAB26-INSULIN AT PH 7.5</PDB_Title>
      <PDB_ID>2WS0</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2WS0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Implications for the Active Form of Human Insulin Based on the Structural Convergence of Highly Active Hormone Analogues.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of an unstable insulin analog with native activity.</PDB_Title>
      <PDB_ID>1J73</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1J73</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Non-standard insulin design: structure-activity relationships at the periphery of the insulin receptor.</PubMed_Title>
      <Author>Weiss, M.A., et al.</Author>
      <Journal>J.Mol.Biol.(2002)315:103-111</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11779231?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF INSULIN</PDB_Title>
      <PDB_ID>1ZEH</PDB_ID>
      <Resolution>1.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZEH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 pro --&gt; Asp insulin analogues.</PubMed_Title>
      <Author>Whittingham, J.L., et al.</Author>
      <Journal>Biochemistry(1998)37:11516-11523</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9708987?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Solution structure of the monomeric [Thr(B27)-&gt;Pro,Pro(B28)-&gt;Thr] insulin mutant (PT insulin)</PDB_Title>
      <PDB_ID>1JCO</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1JCO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Flexibility and bioactivity of insulin: an NMR investigation of the solution structure and folding of an unusually flexible human insulin mutant with increased biological activity.</PubMed_Title>
      <Author>Keller, D., et al.</Author>
      <Journal>Biochemistry(2001)40:10732-10740</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11524020?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>INSULIN MUTANT B16 GLU, B24 GLY, DES-B30, NMR, 20 STRUCTURES</PDB_Title>
      <PDB_ID>1A7F</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1A7F</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A structural switch in a mutant insulin exposes key residues for receptor binding.</PubMed_Title>
      <Author>Ludvigsen, S., et al.</Author>
      <Journal>J.Mol.Biol.(1998)279:1-7</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9636695?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>LVEALYL peptide derived from human insulin chain B, residues 11-17</PDB_Title>
      <PDB_ID>3HYD</PDB_ID>
      <Resolution>1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HYD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular basis for insulin fibril assembly.</PubMed_Title>
      <Author>Ivanova, M.I., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2009)106:18990-18995</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19864624?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Non-standard Design of Unstable Insulin Analogues with Enhanced Activity</PDB_Title>
      <PDB_ID>1JCA</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1JCA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Non-standard insulin design: structure-activity relationships at the periphery of the insulin receptor.</PubMed_Title>
      <Author>Weiss, M.A., et al.</Author>
      <Journal>J.Mol.Biol.(2002)315:103-111</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11779231?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The structure of a mutant insulin uncouples receptor binding from protein allostery. An electrostatic block to the TR transition</PDB_Title>
      <PDB_ID>3BXQ</PDB_ID>
      <Resolution>1.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BXQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design of an active ultrastable single-chain insulin analog: synthesis, structure, and therapeutic implications.</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>J.Biol.Chem.(2008)283:14703-14716</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18332129?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Enhancing the activity of insulin at receptor edge: crystal structure and photo-cross-linking of A8 analogues</PDB_Title>
      <PDB_ID>1RWE</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RWE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Enhancing the activity of insulin at the receptor interface: crystal structure and photo-cross-linking of A8 analogues.</PubMed_Title>
      <Author>Wan, Z., et al.</Author>
      <Journal>Biochemistry(2004)43:16119-16133</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15610006?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>LYS(B28)PRO(B29)-HUMAN INSULIN</PDB_Title>
      <PDB_ID>1LPH</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1LPH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Role of C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB29-human insulin.</PubMed_Title>
      <Author>Ciszak, E., et al.</Author>
      <Journal>Structure(1995)3:615-622</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8590022?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus</PDB_Title>
      <PDB_ID>3JSD</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3JSD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>NMR structure of human insulin mutant HIS-B5-ALA, HIS-B10-ASP PRO-B28-LYS, LYS-B29-PRO, 20 structures</PDB_Title>
      <PDB_ID>2H67</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2H67</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A Conserved Histidine in Insulin Is Required for the Foldability of Human Proinsulin: Structure and function of an Alab5 analog.</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>J.Biol.Chem.(2006)281:24889-24899</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16728398?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human insulin</PDB_Title>
      <PDB_ID>3I3Z</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3I3Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>X-ray investigation of gene-engineered human insulin crystallized from a solution containing polysialic acid.</PubMed_Title>
      <Author>Timofeev, V.I., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.F(2010)66:259-263</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20208155?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>INSULIN MUTANT A8 HIS,(B1, B10, B16, B27)GLU, DES-B30, NMR, 26 STRUCTURES</PDB_Title>
      <PDB_ID>1IOH</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IOH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The relationship between insulin bioactivity and structure in the NH2-terminal A-chain helix.</PubMed_Title>
      <Author>Olsen, H.B., et al.</Author>
      <Journal>J.Mol.Biol.(1998)284:477-488</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9813131?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SEMI-SYNTHETIC HIGHLY ACTIVE ANALOGUE OF HUMAN INSULIN NMEALAB26-DTI-NH2</PDB_Title>
      <PDB_ID>2WRU</PDB_ID>
      <Resolution>1.57</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2WRU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Implications for the Active Form of Human Insulin Based on the Structural Convergence of Highly Active Hormone Analogues.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>The structure of the resorcinol/insulin R6 hexamer</PDB_Title>
      <PDB_ID>1EVR</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1EVR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>R6 hexameric insulin complexed with m-cresol or resorcinol.</PubMed_Title>
      <Author>Smith, G.D., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2000)56:1541-1548</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11092919?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human insulin</PDB_Title>
      <PDB_ID>3I40</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3I40</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>X-ray investigation of gene-engineered human insulin crystallized from a solution containing polysialic acid.</PubMed_Title>
      <Author>Timofeev, V.I., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.F(2010)66:259-263</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20208155?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Insulin fibrillation is the Janus face of induced fit. A chiral clamp stabilizes the native state at the expense of activity</PDB_Title>
      <PDB_ID>3P33</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3P33</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Insulin fibrillation is the Janus face of induced fit.  A chiral clamp stabilizes the native state at the expense of activity</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>FIRST PROTEIN STRUCTURE DETERMINED FROM X-RAY POWDER DIFFRACTION DATA</PDB_Title>
      <PDB_ID>1FU2</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FU2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The first protein crystal structure determined from high-resolution X-ray powder diffraction data: a variant of T3R3 human insulin-zinc complex produced by grinding.</PubMed_Title>
      <Author>Von Dreele, R.B., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2000)56:1549-1553</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11092920?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR Structure of Proinsulin</PDB_Title>
      <PDB_ID>2KQP</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2KQP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structure of proinsulin: connecting domain flexibility and prohormone processing.</PubMed_Title>
      <Author>Yang, Y., et al.</Author>
      <Journal>J.Biol.Chem.(2010)285:7847-7851</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20106974?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Enhancing the activity of insulin by stereospecific unfolding</PDB_Title>
      <PDB_ID>2K91</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2K91</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Enhancing the Activity of a Protein by Stereospecific Unfolding: CONFORMATIONAL LIFE CYCLE OF INSULIN AND ITS EVOLUTIONARY ORIGINS.</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:14586-14596</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19321436?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Design of an Active Ultra-Stable Single-Chain Insulin Analog 20 Structures</PDB_Title>
      <PDB_ID>2JZQ</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2JZQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design of an active ultrastable single-chain insulin analog: synthesis, structure, and therapeutic implications.</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>J.Biol.Chem.(2008)283:14703-14716</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18332129?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE</PDB_Title>
      <PDB_ID>1TYM</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TYM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structure of a complex of hexameric insulin and 4'-hydroxyacetanilide.</PubMed_Title>
      <Author>Smith, G.D., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1994)91:8851-8855</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8090735?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR structure of human insulin mutant His-B10-Asp, Pro-B28-Lys, Lys-B29-Pro, 20 structures</PDB_Title>
      <PDB_ID>2JMN</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2JMN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Mapping the functional surface of insulin by design: structure and function of a novel A-chain analogue.</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>J.Mol.Biol.(1996)264:390-403</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8951384?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human insulin in presence of urea at pH 7.0</PDB_Title>
      <PDB_ID>2OLY</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OLY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic characterization of two novel crystal forms of human insulin induced by chaotropic agents and a shift in pH.</PubMed_Title>
      <Author>Norrman, M., et al.</Author>
      <Journal>Bmc Struct.Biol.(2007)7:83-83</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18093308?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>1.2 A structure of T3R3 human insulin at 100 K</PDB_Title>
      <PDB_ID>1G7A</PDB_ID>
      <Resolution>1.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1G7A</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Phase changes in T(3)R(3)(f) human insulin: temperature or pressure induced?</PubMed_Title>
      <Author>Smith, G.D., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2001)57:1091-1100</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11468392?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN INSULIN TWO DISULFIDE MODEL, NMR, 10 STRUCTURES</PDB_Title>
      <PDB_ID>1VKT</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1VKT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Mapping the functional surface of insulin by design: structure and function of a novel A-chain analogue.</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>J.Mol.Biol.(1996)264:390-403</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8951384?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR Structure of human insulin mutant GLY-B20-D-ALA, GLY-B23-D-ALA PRO-B28-LYS, LYS-B29-PRO, 20 Structures</PDB_Title>
      <PDB_ID>2L1Z</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2L1Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Chiral Protein Engineering and its Application in G Health</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>1E6-A*0201-ALWGPDPAAA Complex, Triclinic</PDB_Title>
      <PDB_ID>3UTT</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3UTT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes.</PubMed_Title>
      <Author>Bulek, A.M., et al.</Author>
      <Journal>Nat.Immunol.(2012)13:283-289</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22245737?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>1E6-A*0201-ALWGPDPAAA Complex, Monoclinic</PDB_Title>
      <PDB_ID>3UTS</PDB_ID>
      <Resolution>2.71</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3UTS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes.</PubMed_Title>
      <Author>Bulek, A.M., et al.</Author>
      <Journal>Nat.Immunol.(2012)13:283-289</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22245737?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN INSULIN-DEGRADING ENZYME IN COMPLEX WITH INSULIN</PDB_Title>
      <PDB_ID>2WBY</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2WBY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular Basis of Catalytic Chamber-Assisted Unfolding and Cleavage of Human Insulin by Human Insulin Degrading Enzyme.</PubMed_Title>
      <Author>Manolopoulou, M., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:14177-14188</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19321446?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE DELTAA1-A4 INSULIN</PDB_Title>
      <PDB_ID>2W44</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2W44</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Insulin Binding to the Insulin Receptor</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Structure and dynamics of des-pentapeptide-insulin in solution: the molten-globule hypothesis.</PDB_Title>
      <PDB_ID>1HIS</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HIS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure and dynamics of des-pentapeptide-insulin in solution: the molten-globule hypothesis.</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1992)89:2379-2383</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/1549601?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN INSULIN DISULFIDE ISOMER, NMR, 10 STRUCTURES</PDB_Title>
      <PDB_ID>1XGL</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1XGL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of a protein in a kinetic trap.</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>Nat.Struct.Biol.(1995)2:129-138</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7749917?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SOLUTION STRUCTURE OF THE SUPERACTIVE MONOMERIC DES-[PHE(B25)] HUMAN INSULIN MUTANT. ELUCIDATION OF THE STRUCTURAL BASIS FOR THE MONOMERIZATION OF THE DES-[PHE(B25)] INSULIN AND THE DIMERIZATION OF NATIVE INSULIN</PDB_Title>
      <PDB_ID>1MHJ</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MHJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structure of the superactive monomeric des-[Phe(B25)] human insulin mutant: elucidation of the structural basis for the monomerization of des-[Phe(B25)] insulin and the dimerization of native insulin.</PubMed_Title>
      <Author>Jorgensen, A.M., et al.</Author>
      <Journal>J.Mol.Biol.(1996)257:684-699</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8648633?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Insulin Mutant A22Gly-B31Lys-B32Arg</PDB_Title>
      <PDB_ID>2KXK</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2KXK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel recombinant insulin analogue with flexible C - terminus in B chain. NMR structure of biosynthetic engineered A22G-B31K-B32R human insulin monomer in water /acetonitrile solution.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of ni human ARG-insulin</PDB_Title>
      <PDB_ID>2R36</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2R36</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Metal induced structural changes observed in hexameric insulin</PubMed_Title>
      <Author>Sreekanth, R., et al.</Author>
      <Journal>Int.J.Biol.Macromol.(2009)44:29-36</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18977386?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF INSULIN</PDB_Title>
      <PDB_ID>1XDA</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1XDA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of a prolonged-acting insulin with albumin-binding properties.</PubMed_Title>
      <Author>Whittingham, J.L., et al.</Author>
      <Journal>Biochemistry(1997)36:2826-2831</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9062110?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL</PDB_Title>
      <PDB_ID>1ZEG</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZEG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 pro --&gt; Asp insulin analogues.</PubMed_Title>
      <Author>Whittingham, J.L., et al.</Author>
      <Journal>Biochemistry(1998)37:11516-11523</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9708987?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR COMPLEXED WITH PHENOL</PDB_Title>
      <PDB_ID>1QIY</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1QIY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Consequences of the B5 Histidine --&gt; Tyrosine Mutation in Human Insulin Characterized by X-Ray Crystallography and Conformational Analysis.</PubMed_Title>
      <Author>Tang, L., et al.</Author>
      <Journal>Biochemistry(1999)38:12041</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10508408?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 'GREEN' SUBSTATE, AVERAGE STRUCTURE</PDB_Title>
      <PDB_ID>4AIY</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4AIY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Unraveling the symmetry ambiguity in a hexamer: calculation of the R6 human insulin structure.</PubMed_Title>
      <Author>ODonoghue, S.I., et al.</Author>
      <Journal>J.Biomol.NMR(2000)16:93-108</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10723989?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human insulin in presence of thiocyanate at pH 6.5</PDB_Title>
      <PDB_ID>2OM1</PDB_ID>
      <Resolution>1.97</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OM1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic characterization of two novel crystal forms of human insulin induced by chaotropic agents and a shift in pH.</PubMed_Title>
      <Author>Norrman, M., et al.</Author>
      <Journal>Bmc Struct.Biol.(2007)7:83-83</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18093308?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Enhancing the activity of insulin by stereospecific unfolding</PDB_Title>
      <PDB_ID>2K9R</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2K9R</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Enhancing the Activity of a Protein by Stereospecific Unfolding: CONFORMATIONAL LIFE CYCLE OF INSULIN AND ITS EVOLUTIONARY ORIGINS.</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:14586-14596</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19321436?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human insulin cocrystallized with protamine</PDB_Title>
      <PDB_ID>2OMI</PDB_ID>
      <Resolution>2.24</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OMI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural characterization of insulin NPH formulations.</PubMed_Title>
      <Author>Norrman, M., et al.</Author>
      <Journal>EUR.J.PHARM.SCI.(2007)30:414-423</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17339105?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS-B10-ASP, VAL-B12-THR, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES</PDB_Title>
      <PDB_ID>1T1P</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1T1P</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>How Insulin Binds: the B-Chain alpha-Helix Contacts the L1 beta-Helix of the Insulin Receptor.</PubMed_Title>
      <Author>Huang, K., et al.</Author>
      <Journal>J.Mol.Biol.(2004)341:529-550</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15276842?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF DESTRIPEPTIDE (B28-B30) INSULIN</PDB_Title>
      <PDB_ID>1HTV</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HTV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of destripeptide (B28-B30) insulin: implications for insulin dissociation.</PubMed_Title>
      <Author>Ye, J., et al.</Author>
      <Journal>Biochim.Biophys.Acta(2001)1547:18-25</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11343787?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>AN ACTIVE MINI-PROINSULIN, M2PI</PDB_Title>
      <PDB_ID>1EFE</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1EFE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution Structure of an Active Mini-Proinsulin, M2PI: Inter-chain Flexibility is Crucial for Insulin Activity</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure Analysis of Cu Human Insulin Derivative</PDB_Title>
      <PDB_ID>3TT8</PDB_ID>
      <Resolution>1.12</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3TT8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure Analysis of Cu Human Insulin Derivative</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTALLOGRAPHIC AND SOLUTION STUDIES OF N-LITHOCHOLYL INSULIN: A NEW GENERATION OF PROLONGED-ACTING INSULINS.</PDB_Title>
      <PDB_ID>1UZ9</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1UZ9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic and Solution Studies of N-Lithocholyl Insulin: A New Generation of Prolonged-Acting Human Insulins</PubMed_Title>
      <Author>Whittingham, J.L., et al.</Author>
      <Journal>Biochemistry(2004)43:5987</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15147182?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>INSULIN, MONOCLINIC CRYSTAL FORM</PDB_Title>
      <PDB_ID>1ZNJ</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZNJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure Determination and Refinement of Two Crystal Forms of Native Insulins</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>NMR structure of human insulin mutant GLY-B8-D-SER, HIS-B10-ASP PRO-B28-LYS, LYS-B29-PRO, 20 structures</PDB_Title>
      <PDB_ID>2HH4</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HH4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Toward the Active Conformation of Insulin: Stereospecific modulation of a structural switch in the B chain.</PubMed_Title>
      <Author>Hua, Q.X., et al.</Author>
      <Journal>J.Biol.Chem.(2006)281:24900-24909</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16762918?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR structure of human insulin mutant glu-b21-d-glu, his-b10 asp pro-b28-lys, lys-b29-pro, 20 structures</PDB_Title>
      <PDB_ID>2KJU</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2KJU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Acceleration of Protein Fibrillation by Chiral Destabilization of Beta-Turn</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>SEMI-SYNTHETIC HIGHLY ACTIVE ANALOGUE OF HUMAN INSULIN D-PROB26-DTI-NH2</PDB_Title>
      <PDB_ID>2WRW</PDB_ID>
      <Resolution>2.41</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2WRW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Implications for the Active Form of Human Insulin Based on the Structural Convergence of Highly Active Hormone Analogues.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN INSULIN MUTANT SERB9GLU</PDB_Title>
      <PDB_ID>1B9E</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1B9E</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of an insulin dimer in an orthorhombic crystal: the structure analysis of a human insulin mutant (B9 Ser--&gt;Glu).</PubMed_Title>
      <Author>Yao, Z.P., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(1999)55:1524-1532</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10489447?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR COMPLEXED WITH RESORCINOL</PDB_Title>
      <PDB_ID>1QIZ</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1QIZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Consequences of the B5 Histidine --&gt; Tyrosine Mutation in Human Insulin Characterized by X-Ray Crystallography and Conformational Analysis.</PubMed_Title>
      <Author>Tang, L., et al.</Author>
      <Journal>Biochemistry(1999)38:12041</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10508408?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF ALLO-ILEA2-INSULIN, AN INACTIVE CHIRAL ANALOGUE: IMPLICATIONS FOR THE MECHANISM OF RECEPTOR</PDB_Title>
      <PDB_ID>1Q4V</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Q4V</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of allo-Ile(A2)-insulin, an inactive chiral analogue: implications for the mechanism of receptor binding.</PubMed_Title>
      <Author>Wan, Z.L., et al.</Author>
      <Journal>Biochemistry(2003)42:12770-12783</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14596591?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04810</Pathway_ID>
      <Pathway_Title>Regulation of actin cytoskeleton</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell motility</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04150</Pathway_ID>
      <Pathway_Title>mTOR signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05215</Pathway_ID>
      <Pathway_Title>Prostate cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04930</Pathway_ID>
      <Pathway_Title>Type II diabetes mellitus</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Endocrine and metabolic diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04930</Pathway_ID>
      <Pathway_Title>Type II diabetes mellitus</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Endocrine and metabolic diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04950</Pathway_ID>
      <Pathway_Title>Maturity onset diabetes of the young</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Endocrine and metabolic diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04932</Pathway_ID>
      <Pathway_Title>Non-alcoholic fatty liver disease (NAFLD)</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Endocrine and metabolic diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04911</Pathway_ID>
      <Pathway_Title>Insulin secretion</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04932</Pathway_ID>
      <Pathway_Title>Non-alcoholic fatty liver disease (NAFLD)</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Endocrine and metabolic diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04911</Pathway_ID>
      <Pathway_Title>Insulin secretion</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04913</Pathway_ID>
      <Pathway_Title>Ovarian steroidogenesis</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04152</Pathway_ID>
      <Pathway_Title>AMPK signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04917</Pathway_ID>
      <Pathway_Title>Prolactin signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04940</Pathway_ID>
      <Pathway_Title>Type I diabetes mellitus</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Endocrine and metabolic diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04914</Pathway_ID>
      <Pathway_Title>Progesterone-mediated oocyte maturation</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04114</Pathway_ID>
      <Pathway_Title>Oocyte meiosis</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell growth and death</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04022</Pathway_ID>
      <Pathway_Title>cGMP-PKG signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04913</Pathway_ID>
      <Pathway_Title>Ovarian steroidogenesis</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04140</Pathway_ID>
      <Pathway_Title>Regulation of autophagy</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Transport and catabolism</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04960</Pathway_ID>
      <Pathway_Title>Aldosterone-regulated sodium reabsorption</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Excretory system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04068</Pathway_ID>
      <Pathway_Title>FoxO signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04910</Pathway_ID>
      <Pathway_Title>Insulin signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Small proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.h.b.b.b.c.html</SCOP_URL>
    <CATH_Class>Class 1: Mainly Alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1efe</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Type>Oligomerization</Site_Type>
    </AllostericSite>
  </AllostericSite_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>